# [Removed]
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Final rule.
**SUMMARY:**
The Food and Drug Administration (FDA) is amending the animal drug regulations by removing those portions that reflect approval of eight new animal drug applications (NADAs). In a notice published elsewhere in this issue of the *Federal Register* , FDA is withdrawing approval of these NADAs.
**DATES:**
This rule is effective November 5, 2010.
**FOR FURTHER INFORMATION CONTACT:**
John Bartkowiak, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9079, e-mail: *[email protected].*
**SUPPLEMENTARY INFORMATION:**
Fort Dodge Animal Health, a Division of Wyeth Holdings, a Wholly Owned Subsidiary of Pfizer, Inc., 235 East 42d St., New York, NY 10017 has requested that FDA withdraw approval of the eight NADAs listed in Table 1 of this document because they are no longer manufactured or marketed.
| NADA No. | Product | Established name of drug(s) |
| --- | --- | --- |
| NADA 11-141 | UNISTAT-2 Type A medicated article | nitromide and sulfanitran. |
| NADA 14-250 | NOVASTAT Type A medicated article | aklomide and sulfanitran. |
| NADA 34-536 | ALKOMIX Type A medicated article | aklomide. |
| NADA 34-537 | NOVASTAT-3 Type A medicated article | aklomide, sulfanitran, and roxarsone. |
| NADA 35-388 | NOVASTAT-W Soluble Powder | aklomide and sulfanitran. |
| NADA 39-666 | UNISTAT-3 Type A medicated article | nitromide, sulfanitran, and roxarsone. |
| NADA 44-015 | TRAMISOL Type A medicated article | levamisole. |
| NADA 45-455 | TRAMISOL Type A medicated article | levamisole. |
In a notice published elsewhere in this issue of the *Federal Register* , FDA gave notice that approval of NADA 11-141, 14-250, 34-536, 34-537, 35-388, 39-666, 44-015, and 45-455, and all supplements and amendments thereto, is withdrawn, effective November 5, 2010. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these withdrawals of approval.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
**List of Subjects**
Animal drugs.
Animal drugs, Foods.
Animal drugs, Animal feeds.
**21 CFR Part 520**
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 520, 556, and 558 are amended as follows:
**PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS**
1. The authority citation for 21 CFR part 520 continues to read as follows:
**Authority:**
21 U.S.C. 360b.
**21 CFR Part 520**
§ 520.2320
2. Remove § 520.2320.
**21 CFR Part 556**
**PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD**
3. The authority citation for 21 CFR part 556 continues to read as follows:
**Authority:**
21 U.S.C. 342, 360b, 371.
§ 556.30
**21 CFR Part 556**
4. Remove § 556.30.
**21 CFR Part 556**
§ 556.220
5. Remove § 556.220.
**21 CFR Part 556**
§ 556.680
**21 CFR Part 556**
6. Remove § 556.680.
**21 CFR Part 558**
**PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS**
7. The authority citation for 21 CFR part 558 continues to read as follows:
**Authority:**
21 U.S.C. 360b, 371.
**21 CFR Part 558**
§ 558.4
8. In § 558.4, in paragraph (d), in the “Category I” table, remove the listing for “Aklomide”; and in the “Category II” table, remove the listings for “Levamisole”, “Nitromide” immediately followed in sequence by “Sulfanitran”, “Nitromide” immediately followed in sequence by “Sulfanitran” and by “Roxarsone”; “Sulfanitran” immediately followed in sequence by “Aklomide”, and the two listings for “Sulfanitran” immediately followed in sequence by “Aklomide” and by “Roxarsone”.
**21 CFR Part 558**
§ 558.35
**21 CFR Part 558**
9. Remove § 558.35.
**21 CFR Part 558**
§ 558.315
**21 CFR Part 558**
10. Remove § 558.315.
**21 CFR Part 558**
§ 558.376
11. Remove § 558.376.
Dated:
Bernadette Dunham,
Director, Center for Veterinary Medicine.